← All indications
Cardiotoxicity
Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.
Drugs by status
Phase 4 trials (6)
Phase 3 trials (32)
- mercaptopurine
- dexrazoxane
- urea
- captopril
- prednisone
- doxorubicin
- empagliflozin
- fluorouracil
- paclitaxel
- naltrexone
- epirubicin
- bleomycin
- leucovorin
- nebivolol
- vincristine
- trastuzumab
- ifosfamide
- cyclophosphamide
- bevacizumab
- ramipril
- carvedilol
- docetaxel
- metoprolol
- cisplatin
- silymarin
- etoposide
- sargramostim
- cytarabine
- tamoxifen
- asparaginase
- +2 more
Phase 2 trials (10)
Phase 1 trials (12)
Organizations
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 3 Indications (20)
- Roche
- AstraZeneca
- National Cancer Institute (NCI)
- Cairo University
- Cancer and Leukemia Group B (CALGB)
- Herbert Irving Comprehensive Cancer Center
- Instituto do Cancer do Estado de São Paulo
- Johns Hopkins University
- New York University
- Southwest Oncology Group
- University of Florence
- University of Ottawa
- Vilnius University
- Fudan University
- University of Cambridge
- Netherlands Cancer Institute
- University of Sao Paulo
- St. Joseph's Children's Hospital of Tampa
- Canadian Institutes of Health Research (CIHR)
- Hospital A.C. Camargo
Organization Involved with Phase 2 Indications (18)
- Advanced Accelerator Applications
- National Institute for Medical Research, Tanzania
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Cedars-Sinai Medical Center
- University of London
- Cornell University
- Harvard University
- Scarborough General Hospital
- Texas Tech University
- University of South Florida
- University of Toronto
- Mayo Clinic
- University of California, San Francisco
- Ruhr University Bochum
- Avera Health
- Kilimanjaro Christian Medical College, Tanzania
- California Breast Cancer Research Program
- Johannes Kepler University
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (5)